Haleon Pakistan Limited (PSX:HALEON)

Market Cap	92.85B
Revenue (ttm)	37.21B
Net Income (ttm)	4.58B
Shares Out	117.05M
EPS (ttm)	39.11
PE Ratio	20.28
Forward PE	n/a
Dividend	20.00 (2.52%)
Ex-Dividend Date	Mar 11, 2025

Volume	19,430
Average Volume	46,071
Open	799.99
Previous Close	792.29
Day's Range	785.00 - 800.00
52-Week Range	180.00 - 975.00
Beta	0.54
RSI	40.58
Earnings Date	Apr 25, 2025

About Haleon Pakistan

Haleon Pakistan Limited engages in the research and development, manufacture, marketing, and sale of consumer healthcare products in Pakistan, Africa, Australia, North America, Asia, the Middle East, and Europe. It offers oral health, pain relief, vitamins and mineral supplements, and respiratory health products. The company sells its products under the Panadol, CaC-1000 Plus, Sensodyne, paradontax, Actified, T-Day, ENO, Herbactive, Hydrozole, Qalsium-D, and Voltral Emulgel brands. It also exports its products to the Philippines and Vietnam. Th...

• Industry: Pharmaceutical Preparations
• Founded: 2015
• Employees: 481
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HALEON

Financial Performance

In 2024, Haleon Pakistan's revenue was 37.21 billion, an increase of 17.70% compared to the previous year's 31.61 billion. Earnings were 4.58 billion, an increase of 359.85%.